Company news
IDEAYA Biosciences, Inc. news in 2021
IDEAYA Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
December 6, 2021
IDEAYA Biosciences to Participate in Investor Conferences in December 2021
November 29, 2021
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
November 28, 2021
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 14, 2021
IDEAYA Biosciences to Participate in Investor Conferences in November 2021
October 31, 2021
IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer
October 17, 2021
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 9, 2021
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
June 27, 2021
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort
May 9, 2021
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021
April 18, 2021
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
April 15, 2021
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
April 14, 2021
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
March 22, 2021
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196
March 10, 2021
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
February 21, 2021
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors
February 16, 2021
IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs
February 7, 2021
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA
January 10, 2021
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
January 4, 2021
Decks in 2021
- JPM Healthcare Conference January 2021
Conference · 25 slides · Jan 11, 2021